Table 2.
Multivariable Cox regression models for the prediction of progression-free survival, cancer-specific survival, and overall survival in 276 high-risk patients treated with radical cystectomy for urothelial carcinoma of the bladder
| Characteristic | Progression-free survival | Cancer-specific survival | Overall survival | ||||||
|---|---|---|---|---|---|---|---|---|---|
| HR | 95% CI | p value | HR | 95% CI | p value | HR | 95% CI | p value | |
| Urethrectomy | 0.48 | 0.26, 0.87 | 0.02 | 0.57 | 0.26, 1.27 | 0.2 | 0.70 | 0.36, 1.35 | 0.3 |
| Urethral FSA performance | 0.76 | 0.52, 1.10 | 0.15 | 0.50 | 0.32, 0.79 | 0.003 | 0.50 | 0.33, 0.74 | < 0.001 |
| Pathology stage | |||||||||
| pT0/pTa/pTis/pT1 | Ref | Ref | Ref | Ref | Ref | Ref | |||
| pT2 | 2.88 | 1.13, 7.33 | 0.03 | 3.34 | 1.26, 8.91 | 0.02 | 2.31 | 1.07, 4.98 | 0.03 |
| pT3/pT4 | 4.01 | 1.75, 9.15 | < 0.001 | 5.50 | 2.27, 13.3 | < 0.001 | 3.46 | 1.77, 6.75 | < 0.001 |
| Lymph node involvement | 1.00 | 0.68, 1.48 | > 0.9 | 1.59 | 0.97, 2.61 | 0.07 | 1.35 | 0.84, 2.16 | 0.2 |
| Positive soft tissue surgical margin | 1.71 | 1.12, 2.62 | 0.01 | 1.41 | 0.82, 2.42 | 0.2 | 1.55 | 0.95, 2.53 | 0.08 |
| NAC | 1.91 | 0.82, 4.41 | 0.13 | 1.22 | 0.48, 3.09 | 0.7 | 1.10 | 0.47, 2.57 | 0.8 |
CIS carcinoma in situ, FSA frozen section analysis, HR hazard ratio, CI confidence interval, NAC neoadjuvant chemotherapy